Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04254419 | Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells | recruiting | Phase 1 | 18 | Nationwide Children's HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06598787 | A Study of BL-B01D1 in Patients With Recurrent Glioblastoma | recruiting | Phase 2 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT01473485 |
| ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors |
| active not recruiting |
| N/A |
| 10 |
| InSightecINDUSTRY |
| 1 |
| May 1, 2025 |
| clinicaltrials |
| NCT05664243 | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 4 | In8bio Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06869577 | A Supportive Group Intervention for Caregivers to Patients Diagnosed With a Glioblastoma(SUGRI) | not yet recruiting | N/A | 24 | Rigshospitalet, DenmarkOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05432518 | Pilot Trial for Treatment of Recurrent Glioblastoma | recruiting | Early Phase 1 | 10 | AHS Cancer Control AlbertaOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06939400 | Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence | not yet recruiting | — | 100 | Zhejiang Provincial People's HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06936046 | Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression | recruiting | Phase 2 | 200 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06929819 | Research on the Safety and Efficacy of Intraoperative Radiation Therapy in Malignant Cerebral Tumor | not yet recruiting | N/A | 200 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Apr 16, 2025 | clinicaltrials |
| NCT04250064 | A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma(LoBULarDIPG) | recruiting | Phase 2 | 40 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06016452 | A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma(CHROME) | recruiting | Phase 2 | 118 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06779487 | Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline(BIO-RIN) | recruiting | — | 200 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06924099 | TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)(TIGER France) | recruiting | — | 430 | NovoCure Ltd.INDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04775485 | A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors(FIREFLY-1) | recruiting | Phase 2 | 141 | Day One Biopharmaceuticals, Inc.INDUSTRY | 11 | Apr 10, 2025 | clinicaltrials |
| NCT06036381 | Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis(GLIO-RAD) | recruiting | — | 1,000 | Tata Memorial CentreOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06687681 | Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas | recruiting | Phase 2 | 40 | Marzieh EbrahimiINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06915649 | Exploration and Evaluation of Amygdalo-Hippocampectomy According to Prof. Coubes' Technique: An Anatomical, Clinical, and Educational Approach | recruiting | — | 3,504 | University Hospital, MontpellierOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06914427 | PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique | not yet recruiting | N/A | 35 | Xijing HospitalOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04164901 | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | active not recruiting | Phase 3 | 331 | Institut de Recherches Internationales ServierOTHER | 11 | Apr 3, 2025 | clinicaltrials |
| NCT04025541 | Analysis of Circulating Tumor Markers in Blood(ALCINA2) | recruiting | N/A | 992 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03849430 | Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients(Glioma2015) | recruiting | — | 750 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05753995 | Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study | active not recruiting | N/A | 20 | Kepler University HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06749925 | Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma | not yet recruiting | Phase 3 | 186 | University of Sao Paulo General HospitalOTHER | 0 | Apr 1, 2025 | clinicaltrials |
| NCT05460507 | Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | recruiting | Phase 1 | 40 | Plus TherapeuticsINDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06221553 | Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG(CMD03DIPG) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT01906385 | Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | recruiting | Phase 1 / Phase 2 | 55 | Plus TherapeuticsINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06323408 | Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas(BZKF-AYA) | not yet recruiting | — | 72 | University Hospital RegensburgOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT05941234 | Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma(IPerGlioGEM) | recruiting | N/A | 120 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06054529 | Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients(GBM-FLUX2) | active not recruiting | — | 2 | AdventHealth Translational Research InstituteOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06781372 | Patient's Derived Organoids for Drug Screening in Glioblastoma(GlioPDO) | not yet recruiting | N/A | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06408428 | Glioma Intraoperative MicroElectroCorticoGraphy(MicroECoGG) | not yet recruiting | N/A | 50 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05274919 | Vascular Signature Mapping of Brain Tumor Genotypes(VASIM) | recruiting | — | 180 | Leiden University Medical CenterOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05769660 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM) | recruiting | Phase 1 | 12 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05565326 | Response Assessment During MR-guided Radiation Therapy for Glioblastoma(MARGA) | recruiting | — | 20 | University of ZurichOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03452579 | Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM | active not recruiting | Phase 2 | 90 | David PeereboomOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | recruiting | Phase 1 / Phase 2 | 24 | Emory UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06845020 | CSF Proteomic Characterization of Glioblastomas | not yet recruiting | — | 15 | Univeridad Autonoma de GuadalajaraOTHER | 0 | Feb 25, 2025 | clinicaltrials |
| NCT05231655 | Ex VIvo DEtermiNed Cancer Therapy(EVIDENT) | recruiting | — | 600 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06831773 | Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma | recruiting | N/A | 23 | Gansu Wuwei Tumor HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT03181477 | Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas(Glio-SIB-Up) | active not recruiting | N/A | 67 | Centre Georges Francois LeclercOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06000787 | MCT for the Harvard/UCSF ROBIN Center | recruiting | N/A | 47 | Brigham and Women's HospitalOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04881032 | AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma(NANO-GBM) | active not recruiting | Phase 1 / Phase 2 | 66 | Centre Jean PerrinOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06140875 | Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF) | recruiting | N/A | 26 | Charite University, Berlin, GermanyOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05473923 | PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas | active not recruiting | Early Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06113705 | Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study. | recruiting | N/A | 75 | Istituto Clinico HumanitasOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06801730 | Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma(NALIRIBVRG) | recruiting | Phase 2 | 38 | Zhifeng Tian,MDOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05911230 | Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases(AiD-GLIO) | recruiting | N/A | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06710249 | Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema(AFBTEdema) | recruiting | Phase 2 | 20 | Peter SiesjöOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05968053 | Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)(DT-MiNi) | recruiting | — | 500 | Beijing Tiantan HospitalOTHER | 1 | Jan 23, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2025source: clinicaltrials